Results 181 to 190 of about 713,346 (360)

Nanoparticle-mediated delivery of angiotensin II receptor antagonist, olmesartan medoxomil into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension in rats [PDF]

, 2009
L. Chen, Kazuya Nakano, Satoshi Kimura, Tetsuya Matoba, Kenji Sunagawa, K Egashira   +5 more
openalex   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Pharmacokinetics and Safety of the Oral Prostaglandin F2alpha Receptor Antagonist OBE022: A First-In-Human Study in Healthy Post-Menopausal Women

, 2018
Ulrike Lorch, Oliver Pohl, Line Marchand, Jean‐Pierre Gotteland   +3 more
openalex   +2 more sources

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Letter to the editor - "Re: Tinea labialis in a patient with Schnitzler syndrome on interleukin-1 receptor antagonist". [PDF]

JAAD Case Rep
Velusamy B, Pincelli T, Sokumbi O.
europepmc   +1 more source

Structure Based Virtual Screening Of Novel Noncompetitive Antagonist Of Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (Ampa) Receptor

, 2018
Mei Lin Duan, Ling Ling Tan, Juan Du, Xiao Yao   +3 more
openalex   +2 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Preclinical study of a new ¹⁷⁷Lu-labeled somatostatin receptor antagonist in HT-29 human colorectal cancer cells.

, 2020
Hossein Behnammanesh, Mostafa Erfani, Maliheh Hajiramezanali, Safura Jokar, Parham Geramifar, Omid Sabzevari, Mohsen Amini, Seyed Mohammad Mazidi, Davood Beiki   +8 more
openalex   +2 more sources

Fas apoptosis inhibitory molecules: more than death‐receptor antagonists in the nervous system [PDF]

, 2016
Laura Planells‐Ferrer, Jorge Urresti, Elena Coccia, Koen M.O. Galenkamp, Isabel Calleja‐Yagüe, Joaquı́n López-Soriano, Paulina Carriba, Bruna Barneda‐Zahonero, Miguel F. Segura, Joan X. Comella   +9 more
openalex   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source